(Q47924396)

6 February 2018

title

Vaccine adjuvants: a priority for vaccine research (English)

1 reference

6 February 2018

1 reference

Donata Medaglini

2

0 references

Robin Shattock

series ordinal

3

object named as

Robin J Shattock

1 reference

6 February 2018

author name string

Ali M Harandi

series ordinal

1

1 reference

6 February 2018

Working Group convened by EUROPRISE

series ordinal

4

1 reference

6 February 2018

language of work or name

English

0 references

publication date

9 January 2010

1 reference

6 February 2018

published in

Vaccine

1 reference

6 February 2018

volume

28

1 reference

6 February 2018

issue

12

1 reference

6 February 2018

page(s)

2363-2366

1 reference

6 February 2018

Aluminium compounds for use in vaccines

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Improving defences at the portal of HIV entry: mucosal and innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Mucosal delivery of vaccine antigens and its advantages in pediatrics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Adoptive transfer of transgenic T cells to study mucosal adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Retinoic acid-dependent regulation of immune responses by dendritic cells and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

The European effort towards the development of mucosal vaccines for poverty-related diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Alum adjuvanticity: unraveling a century old mystery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Molecular and cellular signatures of human vaccine adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Mechanism of action of licensed vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Molecular adjuvants for mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Immunostimulatory combinations: designing the next generation of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

New horizons in adjuvants for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

The perfect mix: recent progress in adjuvant research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

New adjuvants: EU regulatory developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

Vaccine adjuvants: scientific challenges and strategic initiatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.084

10.1016/J.VACCINE.2009.12.084

7 January 2021

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018